Loading organizations...
Pentwater Capital Management is a private investment firm specializing in event-driven strategies across various capital structures. The firm employs a dynamic, disciplined, and opportunistic methodology, focusing on active risk management and capital preservation. Its core offering aims to optimize client returns through strategic investments linked to corporate events.
Established in April 2007 by founder Matthew Halbower, Pentwater’s genesis stemmed from a clear insight. Halbower believed a disciplined investment approach within the event-driven space, coupled with rigorous risk mitigation, could consistently deliver significant value. This vision laid the groundwork for a firm dedicated to identifying and capitalizing on market inefficiencies.
Pentwater Capital Management primarily serves institutional investors and sophisticated clients. The company's vision centers on becoming a leading partner in complex event-driven investing, marked by institutional quality service, operational excellence, and compliance. They aspire to build enduring relationships by consistently applying their deep knowledge to navigate market dynamics.
Pentwater Capital Management has 1 tracked investment across 1 company. The latest tracked deal is $142.0M Series C in Poseida Therapeutics in April 2019.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Apr 22, 2019 | Poseida Therapeutics | $142.0M Series C | Novartis Pharma | Aisling Capital, Boxer Capital, Longitude Capital, Malin Corporation, Perceptive Advisors, Vivo Capital |